Search
Alnylam Pharmaceuticals Inc
ALNYAdd to Watchlist
228.650USD
+1.530+0.67%
Close 08-14 16:00（ET）Quotes delayed by 15 min
30.58BMarket Cap
55.96P/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Alnylam Pharmaceuticals Inc is 7.87, ranking 93 out of 156 in the Pharmaceuticals industry. The average price target is 500.00, with a high of 580.00 and a low of 236.00.
Analyst Rating
Based on
31
analysts
Buy
Current Rating
373.141
Target Price
+64.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Alnylam Pharmaceuticals Inc
ALNY
31
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Regeneron Pharmaceuticals Inc
REGN
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Alnylam Pharmaceuticals Inc's expected revenue for the next quarter?
Alnylam Pharmaceuticals Inc's expected revenue is 1.44B.
What is Alnylam Pharmaceuticals Inc's price target?
Analysts forecast that Alnylam Pharmaceuticals Inc's price target is USD 500.00, with the highest forecast at USD 580.00 and the lowest forecast at USD 236.00.
How have Alnylam Pharmaceuticals IncALNY's recent earnings per share performed?
The market expectation was USD 1.23, while Alnylam Pharmaceuticals IncALNY's earnings per share (EPS) for the previous quarter was USD 1.55. EPS for the next quarter is expected at USD 1.64.
What is the analyst rating for Alnylam Pharmaceuticals Inc?
Based on the ratings of Alnylam Pharmaceuticals Inc's stock from 31 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.